Introduction
Dobutamine is a widely prescribed form of inotropic support for patients with heart failure, but infusion thereof has been associated with hypersensitivity reactions, namely eosinophilia or eosinophilic myocarditis. 1e5 However, it remains unclear whether the true culprit is dobutamine per se or its excipient, sulfite. 6, 7 We report a case of recurrent hypereosinophilia with a skin rash that developed during dobutamine infusion. We used an in vitro flow cytometric assay to show that the hypersensitivity was attributable to sulfite.
Case
A 74-year-old male presented to the allergy clinic with hypereosinophilia (2955/mm 3 ) and a generalized morbiliform rash. He had been hospitalized for aggravated heart failure 2 weeks prior, and had been under supportive management that included dobutamine infusion (Fig. 1) . He had multiple comorbid illnesses, including diabetes mellitus, three-vessel disease, and chronic obstructive pulmonary disease. His initial problems on admission, including dyspnea and edema, gradually improved with supportive management. However, his blood eosinophil count began to increase on hospital day (HD) #5, and a rash developed on HD#12. No fever was evident. Laboratory markers of liver and kidney function were normal. The patient's total serum IgE level was 198 IU/mL. He did not have elevated IgG antibodies against common parasites. We reviewed his prior medical records and found that he had experienced two similar episodes of eosinophilia and/or a rash during two recent hospitalizations necessitated by aggravated heart failure, but no eosinophilia was evident during outpatient follow-ups (Fig. 1) . The first episode occurred 2 years prior; his blood eosinophil count increased from 87/mm 3 on HD#1 to 821/ mm 3 on HD#16. He received dobutamine infusions during that Peer review under responsibility of Japanese Society of Allergology.
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Allergology International j o u r n a l h o m e p a g e : h t t p : / / w w w . e l se v i e r . c o m / l o c a t e / a l i t time. No rash had been noted. The second episode developed 3 months prior, where his blood eosinophil count increased from 36/mm 3 on HD#1 to 2132/mm 3 on HD#7, and a generalized morbiliform rash developed on HD#9. Dobutamine infusion was stopped on HD#8, and the eosinophilia and rash gradually improved (eosinophil count was 572/mm 3 on discharge day, HD#18). Based on this history, we suspected that his current hypereosinophilia and rash were attributable to dobutamine hypersensitivity. We stopped the dobutamine infusion and prescribed a systemic corticosteroid (methylprednisolone, 20 mg per day). The rash and eosinophil count gradually improved (eosinophil count fell from a peak of 6154/mm 3 on HD#17 to 746/mm 3 on HD#23); he was discharged on HD#23. To confirm that dobutamine had caused the problems described above, we performed an in vitro cell stimulation assay. We obtained peripheral blood mononuclear cells (PBMCs) 4 weeks after discontinuation of systemic corticosteroid therapy. We used flow cytometry to measure the in vitro interferon-g (IFN-g) expression levels in T lymphocytes; the method was a slight modification of that reported earlier. 8 We first tested the injectable form of dobutamine (the agent administered during development of hypersensitivity; Dobutamine HCl Pre-mix Injection; 500 mg dobutamine and 52 mg sodium metabisulfite in 5% [w/v] dextrose; 250 mL). We also examined the in vitro response to sodium metabisulfite (Sigma), because earlier expert reports suggested that sulfite hypersensitivity might be in play during dobutamine-associated eosinophilia or eosinophilic myocarditis. 1,2,9 Briefly, PBMCs were isolated from whole blood by centrifugation through Ficoll-Paque-Plus solution (GE Healthcare). The cells were suspended to a concentration of 5 Â 10 6 /mL in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum. Next, 0.1 mL amounts of cell suspension were added to the wells of a 96-well tissue culture plate. Diluted dobutamine pre-mix (in 0.1 mL culture medium) or sodium metabisulfite (also in 0.1 mL culture medium) was added to the wells. The final concentrations were determined as 2 mg/ml (1:1000 dilution) for dobutamine, and 0.208 mg/ml (1:1000 dilution) for sodium metabisulfite, respectively; cytotoxic effects were observed at concentrations higher than 2.08 mg/ml (1:100 dilution) for sodium metabisulfite. The plates were incubated for 3 days (37 C, 5% [v/v] CO 2 , 100% humidity).
For each drug stimulation, IFN-g expression levels in CD8þ T lymphocytes were measured by flow cytometry (Fig. 2A) . Stimulation index (SI) was calculated as 'IFN-g expression levels with drug stimulation divided by the levels at baseline'. All measurements were done in triplicate. IFN-g expression levels increased compared to the baseline when CD8þ T lymphocytes were stimulated with the dobutamine pre-mix (SI 1.5). However, IFN-g expression levels also increased with sodium metabisulfite stimulation (SI 1.7). Such responses were not observed in three healthy volunteers. The difference in SI between the patient and healthy volunteers was statistically significant (Fig. 2B) . Thus, we diagnosed our patient with sulfite hypersensitivity.
Sulfite is commonly found in drugs and food products, and has been suggested to be an unsuspected cause of drug or food hypersensitivity. 10 As suggested in earlier cardiology articles, sulfite has also been suspected to trigger hypersensitivity reactions in patients receiving dobutamine infusions. 1,2,9 However, this possibility has never been directly tested. A recent case report on a patient with eosinophilic endomyocarditis showed that the dobutamine preparation used (which included sulfite) stimulated lymphocytes, but did not separately explore any possible effect of sulfite. 11 Our present finding suggests that it is important to determine the proportion of patients who develop sulfite hypersensitivity when infused with dobutamine preparations. It is unclear whether our patient developed eosinophilic myocarditis caused by sulfite hypersensitivity. However, as his heart failure symptoms improved during dobutamine infusion and supportive management, we speculate that eosinophilic myocarditis was probably not in play. We observed no other relevant systemic sign or symptom, and thus concluded that the sulfite hypersensitivity, presenting with hypereosinophilia and a skin rash, did not meet the criteria for DRESS syndrome.
In vitro assays yield evidence of (only) "immunological sensitization"; such tests cannot prove that sulfite hypersensitivity actually triggers eosinophilia and/or rash. However, the recurrent episodes of hypersensitivity developing upon dobutamine infusion and the positive in vitro response to sulfite strongly support a diagnosis of sulfite hypersensitivity in the present case.
We measured IFN-g levels as the marker for acute phase reaction of CD8þ T lymphocytes to drug stimulation. In the literature, in vitro IFN-g assays have been frequently used as the rapid and relatively convenient diagnostic tools to determine T-cell mediated sensitization to drugs in patients with delayed-type drug hypersensitivity.
12,13 However, we agree that further assays for eosinophilopoietic cytokines, such as IL-5, should be necessary to detect the intrinsic nature of this clinical syndrome. Also, accumulation of cases is needed to clarify the mechanism of sulfite hypersensitivity.
In conclusion, this is the first case report on a patient exhibiting dobutamine infusion-related hypersensitivity to include in vitro immunological assessment of sulfite hypersensitivity. Clinical allergists need to be aware that dobutamine infusion may trigger hypersensitivity reactions (eosinophilia and/or rash). Also, the proportion of patients who are in fact hypersensitive to sulfite, should be explored.
